Volume | 1,755,897 |
|
|||||
News | - | ||||||
Day High | 55.18 | Low High |
|||||
Day Low | 54.70 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Catalent Inc | CTLT | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
54.70 | 54.70 | 55.18 | 54.82 | 54.65 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
10,382 | 1,755,897 | $ 54.99 | $ 96,549,027 | - | 31.8001 - 60.20 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:42:59 | formt | 500 | $ 55.91 | USD |
Catalent (CTLT) Options Flow Summary
Catalent Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
9.9B | 180.74M | - | 4.26B | -256M | -1.42 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Catalent News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CTLT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 55.30 | 55.60 | 54.52 | 54.97 | 1,223,442 | 0.61 | 1.10% |
1 Month | 55.88 | 56.73 | 54.52 | 55.82 | 1,542,950 | 0.03 | 0.05% |
3 Months | 57.36 | 57.73 | 54.52 | 56.23 | 1,772,473 | -1.45 | -2.53% |
6 Months | 39.40 | 60.20 | 36.7387 | 53.39 | 2,222,541 | 16.51 | 41.90% |
1 Year | 37.00 | 60.20 | 31.8001 | 47.40 | 2,518,655 | 18.91 | 51.11% |
3 Years | 102.58 | 142.64 | 31.45 | 63.13 | 2,066,039 | -46.67 | -45.50% |
5 Years | 46.36 | 142.64 | 31.04 | 66.93 | 1,681,888 | 9.55 | 20.60% |
Catalent Description
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents. |